HUTCHMED climbs after on initiating HMPL-A830 global trial in solid tumors

By Reuters News

** Shares of HUTCHMED (China) 0013.HK climb 2.6% to HK$22.5, on course for the biggest one-day pct gain since September 21

** Stock set to snap two straight sessions of fall

** The pharmaceuticals manufacturer says it has initiated the Phase Ia part of a global clinical trial of HMPL-A830 in patients with unresectable, advanced or metastatic solid tumors

** HUTCHMED says its unit, on September 3, entered into an exclusive development and license agreement with a GSK plc unit, granting the GSK unit worldwide rights to develop and commercialize HMPL-A830 with HUTCHMED responsible for the global Phase І development program of HMPL-A830

** YTD, Hong Kong stock up 7.5%, Hang Seng Biotech Index .HSBIO up 11.6%

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.
 

Cryptocurrency-related content is intended solely as news and market commentary. Crypto Derivatives are not available to Retail clients registered with Capital Com (UK) Ltd.